Amneal Pharmaceuticals, Inc. · NASDAQ (us_market)
Healthcare · Drug Manufacturers - Specialty & Generic · United States
Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products in the United States, India, Ireland, and internationally. The company operates through three segments: Affordable Medicines, Specialty, and AvKARE. The Affordable Medicines segment offers dosage forms and delivery systems, which include immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmics, films, transdermal patches, and topicals. The Specialty segment develops, promotes, sells, and distributes pharmaceutical products with a focus on central nervous system and endocrine disorders, including Parkinson's disease. This segment provides Rytary, an oral capsule formulation of carbidopa-levodopa to treat Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism; Unithroid and ONGENTYS for the treatment of hypothyroidism; and CREXONT, which is use for the treatment of Parkinson's disease. The AvKARE segment offers pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. This segment also distributes bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names; and packages and distributes pharmaceuticals and vitamins to its retail and institutional customers. It sells its products through wholesalers, distributors, retail pharmacies, managed care organizations, purchasing co-ops, hospitals, government agencies, institutions, and pharmaceutical companies. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.
| Event Period | Drawdown | Buy Point (Bottom) | Sell Point (Peak) | ticker.setupCols.buyScore | ticker.setupCols.sellScore | Max Return | Algo Return |
|---|---|---|---|---|---|---|---|
DROP2026-02-17$15.19 RISE2026-03-20$11.83 PEAK2026-04-17$13.91 59d | -22.1% 31d | Missed | Missed | — | — | +17.6% 28d | Missed |
DROP2026-02-17$15.19 RISE2026-03-13$11.83 PEAK2026-04-17$13.91 59d | -22.1% 24d | Missed | Missed | — | — | +17.6% 35d | Missed |
DROP2025-03-20$9.01 RISE2025-05-23$7.16 PEAK2025-08-15$9.45 148d | -20.5% 64d | Missed | Missed | — | — | +32.0% 84d | Missed |
DROP2025-03-20$9.01 RISE2025-04-10$6.97 PEAK2025-07-03$8.42 105d | -22.6% 21d | Missed | Missed | — | — | +20.8% 84d | Missed |
DROP2024-11-12$9.25 RISE2025-02-14$7.73 PEAK2025-03-20$9.01 128d | -16.4% 94d | Missed | Missed | — | — | +16.6% 34d | Missed |
DROP2024-11-12$9.25 RISE2024-12-18$7.69 PEAK2025-03-05$8.97 113d | -16.9% 36d | Missed | Missed | — | — | +16.6% 77d | Missed |
DROP2024-03-19$6.34 RISE2024-04-18$5.36 PEAK2024-07-16$7.60 119d | -15.5% 30d | Missed | Missed | — | — | +41.8% 89d | Missed |
DROP2023-08-07$4.59 RISE2023-10-23$3.36 PEAK2023-12-27$6.21 142d | -26.8% 77d | Missed | Missed | — | — | +84.8% 65d | Missed |
DROP2023-02-08$2.70 RISE2023-03-28$1.27 PEAK2023-06-20$2.95 132d | -53.0% 48d | Missed | Missed | — | — | +132.3% 84d | Missed |
DROP2022-08-19$2.71 RISE2022-12-28$1.97 PEAK2023-02-07$2.70 172d | -27.3% 131d | Missed | Missed | — | — | +37.1% 41d | Missed |
DROP2022-08-03$3.62 RISE2022-10-14$1.96 PEAK2022-11-29$2.61 118d | -45.9% 72d | Missed | Missed | — | — | +33.2% 46d | Missed |
DROP2022-02-09$4.87 RISE2022-06-16$3.01 PEAK2022-08-02$3.62 174d | -38.2% 127d | Missed | Missed | — | — | +20.3% 47d | Missed |
DROP2021-12-29$4.91 RISE2022-05-09$3.12 PEAK2022-05-17$3.70 139d | -36.5% 131d | Missed | Missed | — | — | +18.6% 8d | Missed |
DROP2021-10-12$5.85 RISE2021-12-14$3.95 PEAK2021-12-27$5.09 76d | -32.5% 63d | Missed | Missed | — | — | +28.9% 13d | Missed |
DROP2021-03-22$7.38 RISE2021-07-16$4.31 PEAK2021-10-11$5.84 203d | -41.6% 116d | Missed | Missed | — | — | +35.5% 87d | Missed |
1–15 / 20 1 / 2 | |||||||
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Amneal (NASDAQ:AMRX) and the best and worst performers in the generic pharmaceuticals industry.
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Amneal (NASDAQ:AMRX) and the best and worst performers in the generic pharmaceuticals industry.
Barclays analyst Glen Santangelo maintains Amneal Pharmaceuticals (NASDAQ:AMRX) with a Overweight and raises the price target from $15 to $16.
Amneal (AMRX) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Amneal (AMRX) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Amneal trades at $12.64 and has moved in lockstep with the market. Its shares have returned 6.2% over the last six months while the S&P 500 has gained 7.9%.
Amneal trades at $12.64 and has moved in lockstep with the market. Its shares have returned 6.2% over the last six months while the S&P 500 has gained 7.9%.
When companies post strong earnings, the stock generally performs well, just like Amneal Pharmaceuticals, Inc.'s...
When companies post strong earnings, the stock generally performs well, just like Amneal Pharmaceuticals, Inc.'s...
On April 22, 2026 Amneal Pharmaceuticals, Inc. announced that it entered into an agreement to acquire Kashiv BioSciences, LLC. Under the terms of the agreement, Amneal will pay $375 million in cash...
Teva trades at the non-GAAP P/E ratio of 14.93x, which is 65.9% higher than Sanofi's. Find out why TEVA stock is a Sell.
Although the revenue and EPS for Amneal (AMRX) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Although the revenue and EPS for Amneal (AMRX) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
‒ Q1 2026 Net Revenue of $723 million; GAAP Net Income of $62 million; Diluted Income per Share of $0.19 ‒‒ Adjusted EBITDA of $202 million; Adjusted Diluted EPS of $0.27 ‒‒ No Change from Preliminary Results Previously Announced on April 22, 2026 ‒‒ Affirms Previously Announced Increase in 2026 Full Year Guidance ‒ BRIDGEWATER, N.J., May 07, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced its results for the first quarter ended Ma
Amneal Pharmaceuticals (NasdaqGS:AMRX) has entered a definitive agreement to acquire Kashiv BioSciences. The planned deal extends Amneal's reach into biosimilars and specialty therapeutics. The transaction is positioned to expand Amneal's product pipeline and long term competitiveness. For investors tracking Amneal Pharmaceuticals, this agreement comes with the stock trading at $13.41 and 3 year returns of about 7x. The company has also seen a 1 year return of 86.8%, with gains of 5.3% over...
Amneal Pharmaceuticals (NasdaqGS:AMRX) has entered a definitive agreement to acquire Kashiv BioSciences. The planned deal extends Amneal's reach into biosimilars and specialty therapeutics. The transaction is positioned to expand Amneal's product pipeline and long term competitiveness. For investors tracking Amneal Pharmaceuticals, this agreement comes with the stock trading at $13.41 and 3 year returns of about 7x. The company has also seen a 1 year return of 86.8%, with gains of 5.3% over...
Investors need to pay close attention to AMRX stock based on the movements in the options market lately.
Investors need to pay close attention to AMRX stock based on the movements in the options market lately.
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| AMRX | +2.65% | -4.36% | +4.52% | +79.92% |
| XLV | +2.97% | -5.72% | -3.44% | +12.69% |
| Alpha (stock − sector) | -0.32% | +1.36% | +7.97% | +67.23% |
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| StateStreet | passive | 6.79M | $84.46M | 0.00% | Added+65.3% | 2026-03-31 |
| DEShaw | quant | 1.72M | $21.38M | 0.01% | Trimmed-35.4% | 2026-03-31 |
| FidelityFMR | fundamental | 792.0K | $9.84M | 0.00% | Added+110.1% | 2026-03-31 |
| TwoSigma | quant | 282.7K | $3.51M | 0.00% | Trimmed-6.1% | 2026-03-31 |
| RenTech | quant | 276.6K | $3.44M | 0.01% | Added+1586.8% | 2026-03-31 |
| Citadel | multi-strat | 78.1K | $970.85K | 0.00% | New | 2026-03-31 |
| Wellington | fundamental | 62.5K | $776.44K | 0.00% | Trimmed-2.6% | 2026-03-31 |
| TRowePrice | fundamental | 182.9K | $2.27K | 0.00% | Added+26.4% | 2026-03-31 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-08-04upcoming | 0.23 | — | — |
| 2026-05-07 | 0.17 | 0.27 | +59.62% |
| 2026-05-04 | 0.17 | — | — |
| 2026-02-27 | 0.18 | 0.21 | +14.07% |
| 2025-10-30 | 0.14 | 0.17 | +22.89% |
| 2025-08-05 | 0.17 | 0.25 | +42.95% |
| 2025-05-02 | 0.15 | 0.21 | +43.18% |
| 2025-02-28 | 0.15 | 0.12 | -21.08% |
| 2024-11-08 | 0.14 | 0.16 | +18.30% |
| 2024-08-09 | 0.14 | 0.16 | +15.05% |
| 2024-05-03 | 0.09 | 0.14 | +52.07% |
| 2024-03-01 | 0.09 | 0.14 | +56.37% |
| 2023-11-07 | 0.13 | 0.19 | +49.80% |
| 2023-08-04 | 0.10 | 0.19 | +91.36% |
| 2023-05-05 | 0.10 | 0.12 | +25.00% |
| 2023-03-02 | 0.21 | 0.23 | +11.70% |